Dr. Dayou Liu is a highly accomplished expert in the field of production cell line development, with over 20 years of experience. He spent 14 years at Amgen, where he was instrumental in creating dozens of production cell lines for clinical development. Notably, he contributed to four of Amgen's market-leading products, including:

• Prolia/Xgeva: Developed the 2nd generation cell line for post-approval cell line change, achieving over 10g/L.
• Aimovig: Created the anti-CGRPR antibody for migraine treatment.
• EVENITY: Developed the anti-sclerostin antibody for osteoporosis.
• IMDELLTRA: Pioneered the first and only DLL3-targeted bispecific antibody for second-line extensive-stage small cell lung cancer (2L+ ES SCLC).

Following his tenure at Amgen, Dr. Liu joined Merck, where he established the first in-house cell line development (CLD) platform, setting new standards for speed and efficiency in the process. Dr. Liu's innovative contributions have significantly advanced the field of cell line development, making him a respected leader in his domain.